FRIDAY, MAY 16, 2008
Registration opens at 10:00 am. Lunch buffet available from 12:00
13.30 Welcome & Opening words - J. San Miguel, J.L. Harousseau, M. Aapro
13.35 – 14.05 KEYNOTE PRESENTATION: Challenges and Opportunities in the treatment of Multiple Myeloma
– Looking into the Future - M. Attal
SESSION I: Biology and prognostic Indicators - Chair: H. Avet-Loiseau
14.05 – 14.25 Apoptosis and development of Resistance in Multiple Myeloma - G. Morgan
14.25 – 14.50 The use of cytogenetics for defining prognosis and treatment in the clinic. - H. Avet-Loiseau
14.50 – 15.15 New prognostic factors and staging systems in Multiple Myeloma - M. Dimopoulos
SESSION II: The three musketeers in Multiple Myeloma: three presentations on the mechanisms of action
and side-effects of new agents - Chair: M. Aapro
15.15 – 15.35 Lenalidomide (Revlimid®) [incl MOA] - J. San Miguel
15.35 – 15.50 Thalidomide [incl MOA] - J.L. Harousseau
15.50 – 16.10 Bortezomib (Velcade) [incl MOA] - P. Sonneveld
16.10 – 16.40 Coffee Break
16.40 – 17.00 What can we expect from current and planned Clinical Trials? - T. Facon
SESSION III: Disease and Treatment complications - Chair: J.L. Harousseau
17.00 – 17.25 Bone integrity in Multiple Myeloma - E. Terpos
17.25 – 17.50 Side effects profiles of new therapies - M. Boccadoro
17.50 – 18.15 Management of other disease complications - M. Dimopoulos
18.15 Closure of the day.
20.00 Depart from the hotel lobby to Course Dinner.
SATURDAY MAY 17, 2008
SESSION IV: Stem cell transplantation - Chair: J. San Miguel
08.30 – 08.50 The role and timing of autologous stem cell transplantation - J.L. Harousseau
08.50 – 09.10 The role and timing of allogeneic stem cell transplantation - N. Kröger
09.10 – 09.25 How to modulate the GVHD and GVM effects - A. Perez-Simon
09.25 – 09.55 Panel Discussion: Early vs late transplantation & best options for induction,
consolidation & maintenance therapy - J. San Miguel, J.L. Harousseau, A. Perez-Simon, M. Boccadoro,N. Kröger
09.55 – 10.20 Coffee Break
SESSION V: Evaluating Systemic Treatment options - Chair: M. Boccadoro
10.20 – 10.40 What is best for the Young Patient with Newly Diagnosed Disease? - M.V. Mateos
10.40 – 11.15 Optimal Management of Elderly or Frail Patients - including patient case discussion - M. Boccadoro
11.15 – 11.50 Treatment of relapsed and refractory myeloma – including patient case discussion - M. Attal
11.50 – 12.30 Panel discussion: Proposed Treatment Algorithms - Moderator: J. San Miguel - Panelists: All
11.50 – 12.10 First line multiple myeloma patients
12.10 – 12.30 Relapsed/refractory multiple myeloma patients
12.30 – 12.40 Learning Assessments
12.40 - 14.20 Lunch-buffet and certificate delivery
